Pet healthspan focus opens a clearer senior care opportunity

Genflow Biosciences Plc

Pet owners are being urged to focus less on how long dogs and cats live, and more on how well they live as they age. This points to a practical growth area within companion animal health: products and services that help older pets stay mobile, comfortable and mentally engaged for longer.

Advances in veterinary care mean many pets are living longer than before. However, a longer life can also mean more years affected by joint pain, reduced activity, cognitive decline or other age-related conditions. The commercial opportunity is in narrowing that gap between lifespan and healthspan, with earlier support that helps delay or reduce the impact of those problems.

Senior pets often show subtle changes before owners recognise a serious issue. A dog may become less interested in walks, hesitate before using stairs or seem more irritable. A cat may hide more often, stop jumping onto furniture or change its grooming habits. These signs can be mistaken for normal ageing, but they may indicate discomfort, reduced mobility or cognitive changes.

The healthspan theme supports recurring demand rather than one-off treatment. Owners may need ongoing guidance, nutritional support, mobility aids, environmental adjustments and mental enrichment products as their pets age. Each of these areas can form part of a broader senior pet care category.

Diets that support joint health, weight control and cognitive function can become part of long-term care plans. Mobility products, such as ramps, steps and non-slip surfaces, address visible everyday problems in the home. Enrichment tools and routine changes can help maintain mental stimulation, particularly for pets showing signs of cognitive decline.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Genflow reports SIRT6 gene therapy results in aged dogs

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme.

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash.

Age-related disease keeps biotechnology research in focus

Age-related conditions such as glaucoma and sarcopenia continue to support interest in biotechnology research focused on the biology of ageing.

Genflow advances SIRT6 gene therapy

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions.

Search